

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold

David W. Vredevoogd, Thomas Kuilman, Maarten A. Ligtenberg, Julia Boshuizen, Kelly E. Stecker, Beaunelle de Bruijn, Oscar Krijgsman, Xinyao Huang, Juliana C.N. Kenski, Ruben Lacroix, Riccardo Mezzadra, Raquel Gomez-Eerland, Mete Yildiz, Ilknur Dagidir, Georgi Apriamashvili, Nordin Zandhuis, Vincent van der Noort, Nils L. Visser, Christian U. Blank, Maarten Altelaar, Ton N. Schumacher, and Daniel S. Peeper*

*Correspondence: d.peeper@nki.nl

<https://doi.org/10.1016/j.cell.2020.01.005>

(Cell 178, 585–599.e1–e15; July 25, 2019)

When submitting the final high-resolution figures for publication of this article, the Tubulin panel in Figure 3D was accidentally duplicated. This error has now been corrected in the article online. This does not affect any of the conclusions of this study and the authors apologize for any inconvenience this may have caused.




Figure 3D. TRAF2 Targeting Poises Cells to Undergo RIPK1-Dependent Cell Death in Response to T Cell-Derived TNF (corrected)

Western blot analysis of D10 cell lines carrying either a non-targeting control guide (sgCtrl) or a guide targeting *TRAF2* (sg*TRAF2*) after exposure to MART-1 T cells for 0, 2, or 6 h.




Figure 3D. TRAF2 Targeting Poises Cells to Undergo RIPK1-Dependent Cell Death in Response to T Cell-Derived TNF (original)

Western blot analysis of D10 cell lines carrying either a non-targeting control guide (sgCtrl) or a guide targeting *TRAF2* (sgTRAF2) after exposure to MART-1 T cells for 0, 2, or 6 h.